2nd Quarter - Report

340B HEALTH for 340B HEALTH

Period 2nd Quarter 2018 Filed Jul 20, 2018 Signed by Kathryn DiBitetto

Official filing
Firm
340B HEALTH
Client
340B HEALTH
Income
—
Expenses
$270,946
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; FY19 LHHS Appropriations; final 2018 Outpatient Prospective Payment System Rule; proposed and final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties; delay of 340B ceiling price database; S.2312, S.2453, H.R.4710, H.R.4392, H.R.5598, H.R.6071, H.R.6240, H.R.6273, and other legislation relevant to the 340B drug pricing program

LobbyistCovered position, as disclosed
KATHRYN DIBITETTO —
GREG DOGGETT —
DANA LAUREN GANSMAN —
SUSAN PILCH —
AMANDA SELLERS SMITH —
MAUREEN TESTONI New Legislative Aide - Rep. Martin "Marty" Russo (1989-1992); Legislative Aide - Rep. Max Baucus (1992-1995)

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA)

Bills named: H.R. 4710 (115th), H.R. 6071 (115th), H.R. 5598 (115th), S. 2312 (115th), S. 2453 (115th), H.R. 6240 (115th), H.R. 4392 (115th), H.R. 6273 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.